Page 187 - Personalised medicine of fluoropyrimidines using DPYD pharmacogenetics Carin Lunenburg

Cost analysis on DPYD genotype-guided dosing
6
185
Cost parameters (expressed in €) Variable
DPYD genotyping costs Hospitalization nursing ward (per day) Hospitalization ICU (per day)
Baseline value
Standard errora
Sensitivity rangeb
Reference
Additional costs for interventions related to toxicity (expect hospitalization) Grade 0-2
Grade ≥3
86 234
Fixed Fixed
Fixed Fixed
This study11 This study11
Treatment costs capecitabine (per cycle)
144.06 132
30 Fixed
Fixed Fixed
This study11 / Price info drugs16 Guideline15
Capecitabine medication Medical doctor visit
Treatment costs 5-FU per cycle
59.29
20
Fixed
This study / Price info drugs16
5-FU medication + pharmacy preparation Administration at day care Medical doctor visit
276 132
Fixed Fixed
Fixed Fixed
Guideline15 Guideline15
100 636 2,015
Fixed Fixed Fixed
80─120 Fixed Fixed
This study11 Guideline15 Guideline15
a The standard error was calculated on data of this study, or otherwise estimated for parameters not derived from this study. The standard error is used for the probabilistic sensitivity analysis;
b The sensitivity range is calculated by varying the baseline value ±20%. The sensitivity range is used for the one way sensitivity analysis. Abbreviations: 5-FU: 5-fluorouracil; DPYD: gene encoding dihydropyrimidine dehydrogenase; ICU: intensive care unit.